Related Experiment Video
Updated: Jun 4, 2026
08:28
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Effect of blood decrease on micafungin disposition in rats
Hiroki Konishi1, Keizo Fukushima, Masatomo Sudo
1Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nishikiori-kita, Tondabayashi, 548-8540, Japan. konishih@osaka-ohtani.ac.jp
European Journal of Drug Metabolism and Pharmacokinetics
|February 26, 2011
Summary
Severe anemia and low albumin levels minimally impact micafungin (MCFG) clearance. This study shows that reduced blood volume does not significantly alter how the body processes this antifungal drug.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Pharmacology
Background:
- Micafungin (MCFG) is an echinocandin antifungal agent.
- MCFG undergoes extensive hepatic metabolism.
- Factors influencing MCFG pharmacokinetics require elucidation.
Purpose of the Study:
- To investigate the impact of decreased blood volume on MCFG pharmacokinetics in rats.
- To assess the influence of anemia and hypoalbuminemia on MCFG elimination.
Main Methods:
- A rat model was used, with phlebotomy inducing decreased blood volume.
- Hematocrit and plasma albumin levels were reduced to simulate clinical conditions.
- Pharmacokinetic parameters of MCFG were analyzed and compared between control and phlebotomized groups.
Main Results:
- Phlebotomized rats exhibited a 50% decrease in hematocrit and a 15% decrease in plasma albumin.
- No significant differences were observed in total body clearance (CL(tot)) or elimination rate constant (k(e)) for MCFG.
- A minimal increase in the apparent volume of distribution at steady-state (Vd(ss)) was noted.
Conclusions:
- Severe anemia and moderate hypoalbuminemia have a negligible effect on MCFG elimination capacity.
- These findings support clinical observations that hematocrit and albumin levels do not significantly influence MCFG metabolic clearance.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...